Why Don't EMA and FDA Speak With the Same Voice on Flu Treatments? Researchers Investigate
By Zachary Brennan -
Published 13 November 2017
New research published last week digs into cross-national regulatory divergences, with a focus on why some US labels for certain flu treatments say the medicines have not been proven to reduce complications while EU labels claim the opposite.
Categories: News, Europe, US, EMA, FDA, Clinical, Drugs, Government affairs
Tags: Relenza, Tamiflu, regulatory divergence